# US 2016/0256534 A1 · Methods of treating parkinson's disease using viral vectors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256534 A1
- Document ID: US20160256534A1
- Status: Published application
- Kind: A1
- Application number: 15/081,116
- Filed: 2016-03-25
- Published: 2016-09-08
- Earliest claimed: 1999-05-18
- Assignees: Genzyme Corporation; The Regents of the University of California
- Applicants: Genzyme Corporation; The Regents of the University of California
- Inventors: Krystof Bankiewicz; Janet Cunningham
- Web page: https://patentgrep.com/patent/US20160256534A1

## CPC

- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 9/5184: {Virus capsids or envelopes enclosing drugs (liposomes with additional exogenous lipids A61K9/127)}
- A61K 35/761: Adenovirus
- A61K 38/45: Transferases (2)
- A61K 38/51: Lyases (4)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/6901: {Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 48/0025: {wherein the non-active part clearly interacts with the delivered nucleic acid}
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- A61K 51/00: Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K 51/0402: {carboxylic acid carriers, fatty acids (amino acids A61K51/0406)}
- A61P 25/16: Anti-Parkinson drugs
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N 15/86: Viral vectors
- C12N 2750/14142: virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12Y 401/01028: Aromatic-L-amino-acid decarboxylase (4.1.1.28), i.e. tryptophane-decarboxylase
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Methods of delivering viral vectors, particularly recombinant adeno-associated virus (rAAV) virions, to the central nervous system (CNS) using convection enhanced delivery (CED) are provided. The rAAV virions include a nucleic acid sequence encoding a therapeutic polypeptide. The methods can be used for treating CNS disorders such as for treating Parkinson's Disease.

## Claims

### Claim 1

A method for delivering recombinant AAV virions to a subject, comprising administering via convection-enhanced delivery (CED) said rAAV virions into the CNS of the subject, wherein said rAAV virions comprise a nucleic acid sequence encoding a therapeutic polypeptide.

### Claim 2 (depends on 1)

The method of claim 1, wherein the administering is done with an osmotic pump.

### Claim 3 (depends on 1)

The method of claim 1, wherein the administering is done with an infusion pump.

### Claim 4 (depends on 1)

The method of claim 1, wherein the nucleic acid sequence encodes an aromatic-amino-acid decarboxylase (AADC).

### Claim 5 (depends on 1)

The method of claim 1 wherein the subject is a human.

### Claim 6 (depends on 1)

The method of claim 1, wherein the rAAV virions are administered into the striatum.

### Claim 7

A method for delivering recombinant AAV virions to a subject having a CNS disorder, comprising administering via convection-enhanced delivery (CED) said virions into the CNS of the subject, wherein said virions comprise a nucleic acid sequence encoding a therapeutic polypeptide.

### Claim 8 (depends on 7)

The method of claim 7 wherein the CNS disorder is Parkinson's disease, the rAAV virions are administered into the striatum and wherein the nucleic acid sequence encodes AADC

### Claim 9

A method for treating a neurodegenerative disease in a subject, said method comprising:
(a) providing a preparation comprising recombinant adeno-associated virus (rAAV) virions, wherein said virions comprise a nucleic acid sequence that is expressible in transduced cells to provide a therapeutic effect in the subject; and
(b) delivering the preparation to the CNS of the subject using convection-enhanced delivery (CED), wherein said virions transduce neural cells and the nucleic acid sequence is expressed to provide a therapeutic effect in the subject suitable for treating said neurodegenerative disease.

### Claim 10 (depends on 9)

The method of claim 9, wherein the neurodegenerative disease is Parkinson's disease.

### Claim 11 (depends on 9)

The method of claim 9, wherein the nucleic acid sequence expressible in transduced cells encodes AADC or functional fragment thereof.

### Claim 12 (depends on 9)

The method of claim 9, further comprising administering to the subject at least one additional therapeutic compound.

### Claim 13 (depends on 12)

The method of claim 12 wherein the at least one additional therapeutic compound is L-dopa.

### Claim 14 (depends on 13)

The method of claim 13, further comprising administering L-dopa and, optionally, carbidopa to the subject.

### Claim 15

A method of determining levels of dopamine activity in the brain of subject comprising:
(a) administering a labeled tracer to the subject, wherein binding of the tracer to a cell is indicative of dopamine activity; and
(b) imaging the subject's brain to determine the number of cells which bind the labeled tracer, thereby determining levels of dopamine activity in the subject's brain.

### Claim 16 (depends on 15)

The method of claim 15, wherein the labeled tracer is 6-[18F]-fluoro-L-m-tryosine (18F-FMT).

### Claim 17 (depends on 15)

The method of claim 15, wherein the imaging is positron emission tomograph (PET) imaging.
